title: Involvement of PLA2, COX and LOX in Rhinella arenarum oocyte maturation.
abstract: In Rhinella arenarum, progesterone is the physiological nuclear maturation inducer that interacts with the oocyte surface and starts a cascade of events that leads to germinal vesicle breakdown (GVBD). Polyunsaturated fatty acids and their metabolites produced through cyclooxygenase (COX) and lipoxygenase (LOX) pathways play an important role in reproductive processes. In amphibians, to date, the role of arachidonic acid (AA) metabolites in progesterone (P4)-induced oocyte maturation has not been clarified. In this work we studied the participation of three enzymes involved in AA metabolism - phospholipase A2 (PLA2), COX and LOX in Rhinella arenarum oocyte maturation. PLA2 activation induced maturation in Rhinella arenarum oocytes in a dose-dependent manner. Oocytes when treated with 0.08 μM melittin showed the highest response (78 ± 6% GVBD). In follicles, PLA2 activation did not significantly induce maturation at the assayed doses (12 ± 3% GVBD). PLA2 inhibition with quinacrine prevented melittin-induced GVBD in a dose-dependent manner, however PLA2 inactivation did not affect P4-induced maturation. This finding suggests that PLA2 is not the only phospholipase involved in P4-induced maturation in this species. P4-induced oocyte maturation was inhibited by the COX inhibitors indomethacin and rofecoxib (65 ± 3% and 63 ± 3% GVBD, respectively), although COX activity was never blocked by their addition. Follicles showed a similar response following the addition of these inhibitors. Participation of LOX metabolites in maturation seems to be correlated with seasonal variation in ovarian response to P4. During the February to June period (low P4 response), LOX inhibition by nordihydroguaiaretic acid or lysine clonixinate increased maturation by up to 70%. In contrast, during the July to January period (high P4 response), LOX inhibition had no effect on hormone-induced maturation.
authors: Centro de Referencias para Lactobacilos (CERELA)-CONICET,Chacabuco 145,Tucumán,Argentina.
authors: Maria Eugenia
authors: ME
authors: Ortiz
authors: Instituto de Biología,Facultad de Bioqca,Qca. y Farmacia,INSIBIO-UNT,Chacabuco 461,Tucumán,Argentina.
authors: Marta Inés
authors: MI
authors: Bühler
authors: Instituto de Biología,Facultad de Bioqca,Qca. y Farmacia,INSIBIO-UNT,Chacabuco 461,4000. San Miguel de Tucumán,Argentina.
authors: Liliana Isabel
authors: LI
authors: Zelarayán
mesh_terms: D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D002022:Bufo arenarum / Q000502:physiology*; D002478:Cells, Cultured; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D008084:Lipoxygenase / Q000378:metabolism*; D009637:Masoprocol / Q000494:pharmacology; D008555:Melitten / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000502:physiology*; D009866:Oogenesis; D054467:Phospholipases A2 / Q000378:metabolism* / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011796:Quinacrine; D013450:Sulfones / Q000494:pharmacology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D004791:Enzyme Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D008555:Melitten; D016718:Arachidonic Acid; D011374:Progesterone; D009637:Masoprocol; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D054467:Phospholipases A2; D011796:Quinacrine; D007213:Indomethacin